NovoCure Ltd business relationships
Companies named in NovoCure Ltd’s 10-K filed 2026-02-26, and public companies whose annual reports name NovoCure Ltd. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in NovoCure Ltd’s annual report 3
“KEYNOTE D58 was designed and is being conducted as part of a clinical collaboration between Novocure and MSD, a tradename of Merck & Co., Inc. KEYNOTE D58 is currently open and enrolling, and we anticipate completing enrollment by the end of 2026.” SEC filing
“PANOVA-4 was designed and is being conducted as part of a clinical collaboration between Novocure and Roche.” SEC filing
“On September 10, 2018, the Company entered into a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market the Company's Products in China, Hong Kong, Macau and Taiwan ("Greater China").” SEC filing
Companies whose annual reports name NovoCure Ltd 3
“We will purchase the licensed products exclusively from NovoCure.” SEC filing
“License and Collaboration Agreement with NovoCure (Tumor Treating Fields)” SEC filing
“For example, we rely on argenx for VYVGART and VYVGART Hytrulo, NovoCure for OPTUNE, Deciphera for QINLOCK, Innoviva for XACDURO, and BMS for AUGTYRO.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.